Association of renal insufficiency with treatments and outcomes in patients with acute coronary syndrome in China.

[1]  D. Gallo,et al.  P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. , 2019, European heart journal. Cardiovascular pharmacotherapy.

[2]  Mark D. Huffman,et al.  Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.

[3]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[4]  I. Ranasinghe,et al.  Hospital Quality Improvement Initiative for Patients With Acute Coronary Syndromes in China: A Cluster Randomized, Controlled Trial , 2014, Circulation. Cardiovascular quality and outcomes.

[5]  Zhi-Hong Liu.  Nephrology in China , 2013, Nature Reviews Nephrology.

[6]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[7]  Harlan M Krumholz,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[8]  Kyung Hoon Cho,et al.  GFR and cardiovascular outcomes after acute myocardial infarction: results from the Korea Acute Myocardial Infarction Registry. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[10]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[11]  F. Turnbull,et al.  Clinical pathways for acute coronary syndromes in China: protocol for a hospital quality improvement initiative. , 2010, Critical pathways in cardiology.

[12]  L. Wallentin,et al.  Influence of Renal Function on the Effects of Early Revascularization in Non–ST-Elevation Myocardial Infarction: Data From the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) , 2009, Circulation.

[13]  E. Schiffrin,et al.  Chronic Kidney Disease: Effects on the Cardiovascular System , 2007, Circulation.

[14]  B. Psaty,et al.  Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. , 2005, JAMA.

[15]  Robert M Califf,et al.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. , 2004, The New England journal of medicine.

[16]  B. McNeil,et al.  "Renalism": inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. , 2004, Journal of the American Society of Nephrology : JASN.

[17]  E. Antman,et al.  Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. , 2003, Journal of the American College of Cardiology.

[18]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[19]  J. Gore,et al.  Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE) , 2003, Heart.

[20]  A. Jaffe,et al.  Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination , 2002, Annals of Internal Medicine.

[21]  M. Mcclellan,et al.  Association of Renal Insufficiency with Treatment and Outcomes after Myocardial Infarction in Elderly Patients , 2002, Annals of Internal Medicine.

[22]  S. Borzak,et al.  Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. , 2002, American heart journal.

[23]  Á. Avezum,et al.  Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE) , 2002, The Lancet.

[24]  M. Mcclellan,et al.  Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. , 2001, The American journal of medicine.

[25]  M. Mcclellan,et al.  Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. , 2000, Archives of internal medicine.

[26]  A. Levey,et al.  Cardiovascular disease and chronic renal disease: a new paradigm. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  R. Foley,et al.  Epidemiology of cardiovascular disease in chronic renal disease , 2000 .

[28]  M. Pfeffer,et al.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.